These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 26044126)

  • 41. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
    Cai SY; Mennone A; Soroka CJ; Boyer JL
    J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
    Sato Y; Qiu J; Hirose T; Miura T; Sato Y; Kohzuki M; Ito O
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G464-G473. PubMed ID: 33439105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
    Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
    BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors.
    Renner EL; Lake JR; Cragoe EJ; Van Dyke RW; Scharschmidt BF
    Am J Physiol; 1988 Feb; 254(2 Pt 1):G232-41. PubMed ID: 2831731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abnormal expression of MUC1 apomucin and mature MUC1 mucin in biliary epithelial cells in various cystic liver diseases.
    Sasaki M; Nakanuma Y
    Hepatology; 1996 Sep; 24(3):539-43. PubMed ID: 8781320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
    Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of oral ursodeoxycholic acid on bile acids tolerance tests in healthy dogs.
    Abraham LA; Charles JA; Holloway SA
    Aust Vet J; 2004 Mar; 82(3):157-60. PubMed ID: 15088982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects.
    Sauter GH; Thiessen K; Parhofer KG; Jüngst C; Fischer S; Jüngst D
    Digestion; 2004; 70(2):79-83. PubMed ID: 15375335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TGR5 in the Cholangiociliopathies.
    Masyuk TV; Masyuk AI; LaRusso NF
    Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
    Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
    Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats.
    Barone M; Maiorano E; Ladisa R; Pece A; Berloco P; Strazzabosco M; Caruso ML; Valentini AM; Ierardi E; Di Leo A; Francavilla A
    Virchows Arch; 2004 Jun; 444(6):554-60. PubMed ID: 15071740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
    Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
    Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
    Cifuentes-Silva E; Cabello-Verrugio C
    Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stimulation of ATP secretion in the liver by therapeutic bile acids.
    Nathanson MH; Burgstahler AD; Masyuk A; Larusso NF
    Biochem J; 2001 Aug; 358(Pt 1):1-5. PubMed ID: 11485545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.